CN113227146B - 密蛋白18.2结合部分和其用途 - Google Patents

密蛋白18.2结合部分和其用途 Download PDF

Info

Publication number
CN113227146B
CN113227146B CN201980085449.3A CN201980085449A CN113227146B CN 113227146 B CN113227146 B CN 113227146B CN 201980085449 A CN201980085449 A CN 201980085449A CN 113227146 B CN113227146 B CN 113227146B
Authority
CN
China
Prior art keywords
seq
amino acid
nos
acid sequences
cdr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980085449.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN113227146A (zh
Inventor
殷刘松
周铁林
方卓
刘勇
庄秋传
武波
范晓虎
张青山
赵丹
毛杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Jinsirui Science and Technology Biology Corp
Nanjing Legend Biotechnology Co Ltd
Original Assignee
Nanjing Jinsirui Science and Technology Biology Corp
Nanjing Legend Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Jinsirui Science and Technology Biology Corp, Nanjing Legend Biotechnology Co Ltd filed Critical Nanjing Jinsirui Science and Technology Biology Corp
Publication of CN113227146A publication Critical patent/CN113227146A/zh
Application granted granted Critical
Publication of CN113227146B publication Critical patent/CN113227146B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980085449.3A 2018-12-28 2019-12-27 密蛋白18.2结合部分和其用途 Active CN113227146B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2018125052 2018-12-28
CNPCT/CN2018/125052 2018-12-28
CNPCT/CN2019/095827 2019-07-12
CN2019095827 2019-07-12
PCT/CN2019/129017 WO2020135674A1 (en) 2018-12-28 2019-12-27 Claudin18.2 binding moieties and uses thereof

Publications (2)

Publication Number Publication Date
CN113227146A CN113227146A (zh) 2021-08-06
CN113227146B true CN113227146B (zh) 2024-03-01

Family

ID=71127698

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980085449.3A Active CN113227146B (zh) 2018-12-28 2019-12-27 密蛋白18.2结合部分和其用途

Country Status (12)

Country Link
US (1) US12258418B2 (enExample)
EP (1) EP3902839A4 (enExample)
JP (2) JP2022515487A (enExample)
KR (1) KR20210110339A (enExample)
CN (1) CN113227146B (enExample)
AU (1) AU2019415848A1 (enExample)
BR (1) BR112021012608A2 (enExample)
CA (1) CA3125193A1 (enExample)
IL (1) IL284393A (enExample)
MX (1) MX2021007939A (enExample)
SG (1) SG11202106534RA (enExample)
WO (1) WO2020135674A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3138414A1 (en) * 2019-05-16 2020-11-19 Qilu Pharmaceutical Co., Ltd. Antibodyagainst claudin 18a2 and use thereof
PE20221459A1 (es) 2019-11-05 2022-09-21 Lanova Medicines Ltd Conjugados anticuerpo-farmaco dirigido a claudina 18.2
CN113637082A (zh) * 2020-04-27 2021-11-12 启愈生物技术(上海)有限公司 一种靶向人claudin和人PDL1蛋白的双特异抗体及其应用
US12492252B2 (en) 2020-07-01 2025-12-09 Shandong Boan Biotechnology Co., Ltd. Anti-GPC3 antibody, anti-GPC3 chimeric antigen receptor and GPC3/CD3 bispecific antibody
CN113929780A (zh) * 2020-07-13 2022-01-14 北京凯因科技股份有限公司 一种结合密蛋白的用于治疗癌症的人源化抗体
US20240270839A1 (en) * 2020-09-28 2024-08-15 Elpiscience (Suzhou) Biopharma, Ltd. Novel anti-claudin18 antibodies
JP2023548538A (ja) 2020-11-08 2023-11-17 シージェン インコーポレイテッド 併用療法
CN114560941B (zh) * 2020-11-27 2024-01-16 广东东阳光药业股份有限公司 Cldn18.2的抗体及其应用
CN114539402B (zh) * 2020-11-27 2025-06-13 南京北恒生物科技有限公司 靶向Claudin18.2的抗体及其用途
WO2022122709A1 (en) 2020-12-07 2022-06-16 Sotio Biotech A.S. Antibody-drug conjugates based on humanized cldn18.2 antibodies
PE20231561A1 (es) 2020-12-23 2023-10-03 Sotio Biotech A S Conjugados anticuerpo-farmaco especificos para tumores con claudina 18.2
CN113321730B (zh) * 2021-01-11 2023-10-10 上海莱馥医疗科技有限公司 Cldn18.2抗体及其应用
CN116940598A (zh) * 2021-02-08 2023-10-24 山东博安生物技术股份有限公司 用于治疗表达cldn18.2的实体瘤的cldn18.2/cd3双特异性抗体
CN115109154A (zh) * 2021-03-17 2022-09-27 三优生物医药(上海)有限公司 一种靶向cldn18.2的抗体或其抗原结合片段及其应用
CN117083299A (zh) * 2021-04-02 2023-11-17 原启生物科技(上海)有限责任公司 Cldn18.2抗原结合蛋白及其用途
JP7675818B2 (ja) * 2021-05-08 2025-05-13 レメゲン シーオー．，エルティーディー． 抗クローディン－１８．２抗体及びその抗体薬物複合体
KR20230132640A (ko) 2022-03-04 2023-09-15 앱티스 주식회사 티올 반응성 에디티브를 이용한 항체-약물 컨쥬게이트의 제조 수율을 높이는 방법
WO2024096564A1 (ko) 2022-11-01 2024-05-10 앱티스 주식회사 항-클라우딘18.2 항체를 포함하는 항체-약물 컨쥬게이트 및 이의 암에 대한 치료용도
TW202434307A (zh) 2023-01-18 2024-09-01 大陸商泰勵生物科技（上海）有限公司 抗體偶聯藥物及其用途
CN116284224B (zh) * 2023-05-12 2023-07-25 中国农业大学 一种结合Claudin 18.2的环肽及其应用
WO2025038602A1 (en) * 2023-08-14 2025-02-20 Ginkgo Bioworks, Inc. Immune cell stimulatory sequences
WO2025059162A1 (en) 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells
WO2025072299A1 (en) * 2023-09-25 2025-04-03 Duke University Compositions comprising hiv envelopes to induce hiv-1 antibodies
CN120829517A (zh) * 2024-04-22 2025-10-24 鲁南新时代生物技术有限公司 抗cldn18.2/cd3双特异性抗体及用途
WO2025251228A1 (en) 2024-06-05 2025-12-11 Nuwacell Biotechnologies Co., Ltd. Cldn18.2-targeting chimeric antigen receptor and engineered cell

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103509114A (zh) * 2005-11-24 2014-01-15 加尼梅德药物公司 用于治疗癌症的针对密蛋白-18的单克隆抗体
CN104427999A (zh) * 2012-05-23 2015-03-18 加尼梅德药物公司 用于治疗癌症的涉及针对密蛋白18.2之抗体的联合治疗
CN105073777A (zh) * 2013-02-20 2015-11-18 咖尼米德制药股份公司 用于治疗癌症的涉及抗密蛋白18.2抗体的组合疗法
CN109790222A (zh) * 2016-07-08 2019-05-21 科济生物医药（上海）有限公司 抗密蛋白18a2的抗体及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1997832A1 (en) * 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
WO2013174403A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
CN105315375B (zh) * 2014-07-17 2021-04-23 恺兴生命科技(上海)有限公司 靶向cld18a2的t淋巴细胞及其制备方法和应用
WO2016165762A1 (en) 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
WO2016180468A1 (en) * 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Claudin-18.2-specific immunoreceptors and t cell epitopes
IL276830B2 (en) * 2018-03-08 2025-08-01 Phanes Therapeutics Inc Anti-claudin 18.2 antibodies and uses thereof
AU2019270865B2 (en) * 2018-05-18 2023-03-30 LaNova Medicines Limited Anti-claudin 18.2 antibodies and uses thereof
EP3917564A4 (en) * 2019-02-01 2022-12-21 NovaRock Biotherapeutics, Ltd. ANTI-CLAUDINE 18 ANTIBODIES AND THEIR METHODS OF USE
US20220306765A1 (en) * 2019-08-20 2022-09-29 Suzhou Transcenta Therapeutics Co., Ltd. Novel anti-cldn18.2 antibodies

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103509114A (zh) * 2005-11-24 2014-01-15 加尼梅德药物公司 用于治疗癌症的针对密蛋白-18的单克隆抗体
CN104427999A (zh) * 2012-05-23 2015-03-18 加尼梅德药物公司 用于治疗癌症的涉及针对密蛋白18.2之抗体的联合治疗
CN105073777A (zh) * 2013-02-20 2015-11-18 咖尼米德制药股份公司 用于治疗癌症的涉及抗密蛋白18.2抗体的组合疗法
CN109790222A (zh) * 2016-07-08 2019-05-21 科济生物医药（上海）有限公司 抗密蛋白18a2的抗体及其应用

Also Published As

Publication number Publication date
CA3125193A1 (en) 2020-07-02
BR112021012608A2 (pt) 2021-09-08
MX2021007939A (es) 2021-10-22
KR20210110339A (ko) 2021-09-07
EP3902839A1 (en) 2021-11-03
US20220073643A1 (en) 2022-03-10
AU2019415848A1 (en) 2021-08-19
US12258418B2 (en) 2025-03-25
JP2024125370A (ja) 2024-09-18
IL284393A (en) 2021-08-31
JP2022515487A (ja) 2022-02-18
CN113227146A (zh) 2021-08-06
JP7724332B2 (ja) 2025-08-15
SG11202106534RA (en) 2021-07-29
WO2020135674A1 (en) 2020-07-02
AU2019415848A8 (en) 2021-09-02
EP3902839A4 (en) 2022-12-14

Similar Documents

Publication Publication Date Title
CN113227146B (zh) 密蛋白18.2结合部分和其用途
JP2024059872A (ja) 新規抗ｃｃｒ８抗体
ES2616355T3 (es) Anticuerpos para el receptor humano de muerte programada PD-1
EP3575322A1 (en) Anti-pd-1 monoclonal antibody, and preparation method therefor and application thereof
JP2020504627A (ja) 抗ｐｄ−１抗体及びその使用
CN113195542A (zh) Cd30-结合部分、嵌合抗原受体及其用途
KR20240158314A (ko) 새로운 면역 조절제의 개발 및 적용
KR20240038043A (ko) 약학적 조성물 및 용도
CN116390953A (zh) 靶向人密蛋白18.2的抗体及其用途
CN110172099B (zh) 抗lag-3人源化单克隆抗体分子，抗原结合片段及其医药用途
JP2025524390A (ja) 抗ｃｌｄｎ１８．２抗体並びにその医薬組成物及び使用
WO2023138579A1 (zh) 抗b7-h7抗体或其抗原结合片段及制备方法和应用
CN119161478A (zh) α5β1整合素结合剂及其用途
WO2023186113A1 (zh) 靶向pd-l1和cd40的抗原结合蛋白及其制备和应用
JP2024542914A (ja) ヒトｃｘｃｌ１６抗体およびその使用
TW202144432A (zh) 磷脂醯肌醇蛋白聚糖－２結合部分、嵌合抗原受體及其用途
JP2023536630A (ja) Ｐｄ－ｌ１結合性作用剤およびその使用
WO2021107082A1 (ja) 癌性腹膜炎の治療薬
TWI835166B (zh) 靶向pd-1和/或ox40的特異性結合蛋白及其應用
WO2025237420A1 (en) Her2 targetting antibodies, chimeric antigen receptors, and uses thereof
TWI894360B (zh) 抗tigit抗體及雙抗體和它們的應用
EA047760B1 (ru) Группы, связывающие клаудин 18.2, и их использование
EP4494655A1 (en) Combination of multi-specific molecule and immune checkpoint inhibitor
WO2019174637A1 (zh) 一种针对tim-3的全人源化抗体分子、抗原结合片段及其医药用途
HK40089230A (zh) 药物组合物及用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant